When Should You Get the Shingles Vaccine?

What is shingles and why does the vaccine matter?

Shingles (herpes zoster) is a painful rash caused by reactivation of the varicella-zoster virus — the same virus that causes chickenpox. After a chickenpox infection, the virus remains dormant in nerve tissue. Decades later, particularly when the immune system weakens with age, the virus can reactivate.

The most serious complication is postherpetic neuralgia — nerve pain that can persist for months to years after the rash clears, and that is significantly harder to treat than the initial infection. Shingrix is 91% effective at preventing postherpetic neuralgia in adults 50 and older 3Ref 3Centers for Disease Control and Prevention (2024).Shingles Vaccination.Shingrix 97% effective in adults 50–69; 91% effective in adults 70+; 91% effective against postherpetic neuralgia in adults 50+; protection maintained at least 7 years; common side effects (arm soreness, fatigue, headache, low-grade fever). Vaccination substantially reduces both the risk of developing shingles and the severity of complications if shingles does occur 1Ref 1Dooling KL, Guo A, Patel M, et al. (2018).Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Shingrix recommended for all adults 50 and older; two-dose schedule and intervals; recommendation applies to those with prior shingles or prior Zostavax; no upper age limit; side-effect profile; dosing for immunocompromised adults2Ref 2Cunningham AL, Lal H, Kovac M, et al. (2016).Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.ZOE-70 trial: two doses of Shingrix (HZ/su) demonstrated 89.8% efficacy against herpes zoster in approximately 14,000 adults aged 70 and older.

Who is the Shingrix vaccine recommended for?

Shingrix is recommended for all adults 50 and older, with no upper age limit 1Ref 1Dooling KL, Guo A, Patel M, et al. (2018).Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Shingrix recommended for all adults 50 and older; two-dose schedule and intervals; recommendation applies to those with prior shingles or prior Zostavax; no upper age limit; side-effect profile; dosing for immunocompromised adults. Adults well into their 70s, 80s, and beyond are encouraged to be vaccinated — older age is associated with higher risk of shingles and its complications. In the ZOE-70 clinical trial in adults 70 and older, two doses of Shingrix were 89.8% effective against shingles 2Ref 2Cunningham AL, Lal H, Kovac M, et al. (2016).Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.ZOE-70 trial: two doses of Shingrix (HZ/su) demonstrated 89.8% efficacy against herpes zoster in approximately 14,000 adults aged 70 and older.

The recommendation applies to: - Adults who have had chickenpox (which includes most adults who grew up before widespread vaccination) - Adults who have had shingles before — the vaccine helps reduce the risk of recurrence - Adults who previously received the older Zostavax single-dose vaccine — Shingrix provides stronger protection and is preferred 1Ref 1Dooling KL, Guo A, Patel M, et al. (2018).Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Shingrix recommended for all adults 50 and older; two-dose schedule and intervals; recommendation applies to those with prior shingles or prior Zostavax; no upper age limit; side-effect profile; dosing for immunocompromised adults

People with immunocompromising conditions (HIV, cancer, organ transplant, high-dose steroids, biologic medications) are at higher risk of shingles and may have a modified schedule; a clinician should guide timing 4Ref 4Centers for Disease Control and Prevention (2024).Clinical Considerations for Shingrix Use in Immunocompromised Adults Aged ≥19 Years.Shingrix recommended for immunocompromised adults aged 19 and older (non-live vaccine); modified dosing schedule (1–2 months apart); timing considerations around chemotherapy and biologic medications. Pregnant people should generally defer vaccination.

What is the Shingrix dosing schedule?

Shingrix is given as two doses. The standard interval between doses is two to six months. For people who are immunocompromised, a shorter interval of one to two months may be recommended 1Ref 1Dooling KL, Guo A, Patel M, et al. (2018).Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Shingrix recommended for all adults 50 and older; two-dose schedule and intervals; recommendation applies to those with prior shingles or prior Zostavax; no upper age limit; side-effect profile; dosing for immunocompromised adults4Ref 4Centers for Disease Control and Prevention (2024).Clinical Considerations for Shingrix Use in Immunocompromised Adults Aged ≥19 Years.Shingrix recommended for immunocompromised adults aged 19 and older (non-live vaccine); modified dosing schedule (1–2 months apart); timing considerations around chemotherapy and biologic medications.

Shingrix is a non-live (recombinant) vaccine. This matters because people who cannot receive live vaccines due to immune suppression can generally still receive Shingrix — though timing relative to certain therapies (for example, chemotherapy) should be planned with a clinician.

If you had your first dose but have not yet received the second, you do not need to start over — complete the series.

What should you expect after the shot?

Shingrix commonly causes arm soreness, redness, or swelling at the injection site. Many people experience fatigue, headache, muscle pain, or a low-grade fever for a day or two after each dose — particularly the second 1Ref 1Dooling KL, Guo A, Patel M, et al. (2018).Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.Shingrix recommended for all adults 50 and older; two-dose schedule and intervals; recommendation applies to those with prior shingles or prior Zostavax; no upper age limit; side-effect profile; dosing for immunocompromised adults3Ref 3Centers for Disease Control and Prevention (2024).Shingles Vaccination.Shingrix 97% effective in adults 50–69; 91% effective in adults 70+; 91% effective against postherpetic neuralgia in adults 50+; protection maintained at least 7 years; common side effects (arm soreness, fatigue, headache, low-grade fever). These reactions reflect an immune response and are expected and short-lived. Planning the second dose around a day when side effects would be manageable (not immediately before a demanding event) is sensible.

Serious allergic reactions are rare. If you develop hives, facial swelling, or difficulty breathing after leaving the clinic, seek emergency care immediately.

How do you get vaccinated and what does it cost?

Shingrix is available at primary care offices, pharmacies, and many urgent care clinics. Coverage varies: - Medicare Part D typically covers Shingrix, though cost-sharing differs by plan - Most private insurance plans cover it under preventive care benefits - Some patients may face out-of-pocket costs; assistance programs may be available

Ask about your coverage before the appointment. A primary care clinician is the best first stop — they can review your full health picture, confirm the right timing for both doses, and flag any interactions with your current medications or conditions.